Weekly CODE chemotherapy with recombinant human granulocyte colony-stimulating factor for relapsed or refractory small cell lung cancer.

Sato,K; Tsuchiya,S; Minato,K; Sunaga,N; Ishihara,S I; Makimoto,T; Naruse,I; Hoshino,H; Watanabe,S; Saitoh,R; Mori,M

doi:10.3892/or.7.5.1135

Weekly CODE chemotherapy with recombinant human granulocyte colony-stimulating factor for relapsed or refractory small cell lung cancer.

Authors:
- K Sato
- S Tsuchiya
- K Minato
- N Sunaga
- S I Ishihara
- T Makimoto
- I Naruse
- H Hoshino
- S Watanabe
- R Saitoh
- M Mori
View Affiliations

Affiliations: Department of Internal Medicine, National Nishi-Gunma Hospital, Shibukawa, Gunma 377-8511, Japan. satouk@nngh.hosp.go.jp
Published online on: September 1, 2000 https://doi.org/10.3892/or.7.5.1135
Pages: 1135-1144

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We used cisplatin, vincristine, doxorubicin, and etoposide (CODE) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) weekly for salvage chemotherapy in relapsed or refractory small cell lung cancer (SCLC). We reviewed the medical charts of patients between January 1993 and December 1996 at the National Nishi-Gunma Hospital. Twenty patients were treated with salvage chemotherapy. The overall response rate was 55.0%. The median survival time of extensive disease patients from the start of CODE therapy was 23 weeks and the 1-year survival rate was 21.0%. Toxicities were severe, especially in myelosuppression. CODE could be selected as a salvage therapy for chemotherapy- relapsed SCLC cases.